Fingolimod has disease modifying effect on relapsing-remitting multiple sclerosis. Heart rate decrease after fingolimod initiation requires a clinical vigilance. Predefined status of autonomic regulation predicts magnitude of heart rate decrease. Patients at risk for greater heart rate decrease can be identified.